Actively Recruiting
Retina is a Marker for Cerebrovascular Heath
Led by Mayo Clinic · Updated on 2025-07-23
100
Participants Needed
1
Research Sites
276 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.
CONDITIONS
Official Title
Retina is a Marker for Cerebrovascular Heath
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of CADASIL, sporadic white matter disease (WMD), or lobar cerebral microbleeds (CMB)
- Age-matched healthy controls (such as patient's spouse or unrelated friends without SVD)
You will not qualify if you...
- Younger than 18 years old
- Pregnant
- Breastfeeding
- Unable to follow commands
- Unable to tolerate MRI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
Actively Recruiting
Research Team
M
Meredith McDonald
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here